Current Report Filing (8-k)
March 21 2017 - 6:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2017
Minerva Neurosciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36517
|
|
26-0784194
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
1601 Trapelo Road
Suite 284
Waltham,
MA
|
|
02451
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(Registrants telephone number, including area code): (617) 600-7373
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On March 16, 2017 and March 17, 2017, certain investors in Minerva
Neurosciences, Inc.s (the Company) previously announced March 2015 private placement exercised their warrants. Upon exercise, the Company issued the investors an aggregate of 1,418,439 shares of the Companys common stock. The
Company received gross proceeds of $8,187,229.91 from the exercise prices of the exercised warrants.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
MINERVA NEUROSCIENCES, INC.
|
|
|
By:
|
|
/s/ Mark S. Levine
|
Name:
|
|
Mark S. Levine
|
Title:
|
|
Senior Vice President, General Counsel and Secretary
|
Date: March 21, 2017
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024